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riddle  East  Respiratory  S
ore  than  three  years  after  the  ﬁrst  case
as described,  Middle  East  Respiratory  Syndrome
MERS) coronavirus  continues  to  cause  sporadic
ases in the  community  as  well  as  intermittent
ajor hospital  outbreaks.  Poor  infection  control
ractices, hospital  overcrowding  and  delayed  diag-
oses have  been  identiﬁed  as  root  causes  for
ealthcare-associated  transmission.  The  case  fatal-
ty rate  is  approximately  35%  [1].  However,  the
ortality  rate  for  patients  hospitalized  with  lower
espiratory  tract  illness  is  higher,  and  for  those  who
equire intensive  care  admission,  the  reported  mor-
ality rate  reaches  65—90%  [2].  So  far,  no  therapy
as been  proven  to  be  effective,  and  our  under-
tanding of  the  disease  pathogenesis  in  humans
emains incomplete.  An  autopsy  of  a  patient  with
ERS that  has  been  published  identiﬁed  signiﬁcant
arenchymal involvement  of  the  lower  respiratory
ract [3].  In  a  review  of  37  patients,  Corman  et  al.
dentiﬁed  high  and  protracted  viral  replication  in
he lower  respiratory  tract  of  seriously  ill  MERS
atients [4].  These  ﬁndings  suggest  that  the  early
se of  sufﬁciently  potent  antiviral  regimens  may
eneﬁt patients  by  reducing  viral  activity,  preven-
ing lung  damage  and  decreasing  the  load  of  viral
hedding  among  these  patients.  Delayed  diagnoses
nd  a  lack  of  well-deﬁned  animal  models  have  not
llowed  for  quick  progress  on  drug  development
or MERS  [5].  Nevertheless,  some  progress  has  been
ade in  developing  therapeutics  and  is  discussed  in
his article.  Further  work  is  still  needed.
Immunotherapy  with  viral-speciﬁc  antibodies
epresents a  promising  avenue  of  therapy  for  MERS
nd has  been  considered  to  be  a high  priority
or clinical  testing  [6,7]. A  research  protocol  for
ollecting  and  testing  convalescent  plasma  from
reviously  infected  patients  and  infected  patients,
ith the  goal  of  transfusing  protective  antibodies  to
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ERS  patients,  has  been  formulated  [8]. This  pro-
ocol has  led  to  the  establishment  of  a  network  of
nvestigators,  the  characterization  of  patients  with
ERS and  the  screening  of  previously  or  potentially
xposed individuals.  Recent  data  suggest  that  neu-
ralizing antibodies  develop  in  most  survivors  [9].
hese individuals  could  donate  plasma  for  the  clin-
cal study  or production  of hyperimmune  globulins.
he work  is  still  in  progress  to  determine  whether
his is  a feasible  large-scale  therapy.
Substantial progress  has  been  made  on  the  pro-
uction  of  MERS-CoV-speciﬁc  neutralizing  antibod-
es in  humans  as  well  as  ‘‘humanized’’  MERS-CoV
eutralizing antibodies  that  show  antiviral  activity
n animal  models  [10—12].  A  human  polyclonal  anti-
ody product  has  been  generated  from  cows  using
olecular  technologies  in  which  bovine  Ig  genes
ere knocked  out  and  human  immunoglobulin-
roducing  genes  were  inserted  into  the  genome.
n addition,  mice  were  genetically  modiﬁed  to  pro-
uce human  monoclonal  antibodies  when  they  were
xposed  to  and  challenged  with  the  MERS-CoV  anti-
en [13]. Antibodies  produced  in  large  quantities
ere then  puriﬁed,  and  the  neutralizing  activ-
ty was  measured  and  made  available  for  testing
n MERS  animal  models.  These  technologies  are
urrently  in  various  stages  of  development  and  rep-
esent a promising  and  potential  intervention  that
ay be  tested  in  future  clinical  trials.
Repurposed  medications  are  another  category
f potential  therapeutics  that  is  of  great  interest
14]. Public  Health  England,  in  collaboration  with
he International  Severe  Acute  and  Emerging  Respi-
atory Infection  Consortium  (ISARIC),  identiﬁed
nterferons (+/−  ribavirin),  lopinavir,  nitazoxanide
nd chloroquine  and  as  potential  therapeutics
hat have  sufﬁcient  promise  for  future  investiga-
ion. Both  interferon-beta  and  ritonavir-boosted
nces. Published by Elsevier Limited. All rights reserved.
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lopinavir  have  shown  to  have  antiviral  effects  in  the
common marmoset  model  of  MERS  [15].  However,
none of  these  potential  therapies  have  sufﬁcient
clinical data  to  suggest  that  they  be  used  rou-
tinely in  clinical  care;  instead,  they  were  tested
in the  context  of  an  appropriately  designed  clinical
trial. There  have  been  several  observational  reports
evaluating  the  efﬁcacy  of  interferons,  which  are
often used  in  conjunction  with  ribavirin  [16]. How-
ever, it  is difﬁcult  to  identify  the  true  efﬁcacy
from these  studies  because  of  the  small  sample
size and  need  to  adequately  address  the  indication
bias. Systemic  corticosteroids,  ribavirin  monother-
apy, intravenous  immunoglobulin  and  mycophenolic
acid/myophenolate  mofetil  appear  to  be  associ-
ated  with  a  greater  likelihood  of  causing  harm
rather than  having  potential  beneﬁts  and  have
not been  prioritized  for  evaluation.  Evolving  and
new evidence  should  be  continually  reassessed.
There are  also  ongoing  screening  efforts  to  iden-
tify novel  inhibitors:  a  nucleotide  prodrug  called
GS-5734 inhibits  Ebola  in  macaques  and  has  been
used to  treat  several  Ebola  patients.  GS-5734  is  a
potent inhibitor  of  coronaviruses,  including  MERS-
CoV in  vitro  (Travis  Warren,  Presented  at  ICAAC
2015). Studies  in  animal  models  are  in  progress.
The episodic  nature  of  MERS-CoV  infections  and
the relatively  low  numbers  of  reported  cases  at
any given  hospital  or  region  present  a  practical
challenge for  conducting  clinical  trials.  Therefore,
collaboration among  investigators  and  centers  will
be critical  for  conducting  adequately  powered  ther-
apeutic clinical  trials.  Scientiﬁcally  valid  clinical
evidence regarding  safety  and  efﬁcacy  must  drive
and inform  the  incorporation  of  new  therapeu-
tics into  clinical  practice.  Acknowledging  that  most
potential  therapies  will  not  ultimately  be  effec-
tive, the  research  infrastructure  should  consider
an  adaptive  design  that  allows  the  comparison  of
multiple  treatment  regimens  to  an  identiﬁed  con-
current control  group.
Collaborative  national  and  international  intel-
lectual,  scientiﬁc,  logistical,  regulatory  and  ﬁnan-
cial support  has  already  begun  in  KSA  [17,18].
National  and  international  investigators  have  devel-
oped draft  protocols  of  observational  studies  to
help identify  risk  factors  for  acquiring  MERS  to
better  characterize  the  clinical  illness,  identify
risk factors  for  illness  progression  and  clarify  the
mortality  rate  among  all  patients  fulﬁlling  the
case deﬁnition  of  MERS  (much  of  this  work  has
already been  performed  in  KSA  and  internationally)
[19,20].  On  the  other  hand,  protocols  for  therapeu-
tic trial(s)  of  the  most  promising  potential  therapies
need to  be  developed.  These  protocols  must  be
ready and  approved  by  the  ethics  committeesEditorial
n  different  hospitals  and  must  be  utilized  to
nroll sporadic  patients  as  well  as  cases  during
utbreaks. There  should  also  be  a  coordinating
enter with  a mandate  to  support  protocol  devel-
pment, prepare  potential  study  sites,  and  ensure
hat all  needed  elements  are  in  place  for  clinical
rials, such  as  IRB  approvals,  consent  forms,  data
anagement  ability,  and  research  coordinators.
ventually, mechanisms  to  share  data  and  spec-
mens throughout  the  national  and  international
cientiﬁc communities  need  to  be  established.  This
esearch infrastructure,  including  the  investigative
taff, needs  to  be  present  or  mobile  to  sites,  quickly
n the  hopes  of  enrolling  patients.  In  addition  to
reatment-based  evaluations,  non-treatment  based
esearch priorities  and  gaps  should  be  addressed.
The journey  toward  an  effective  therapy  for
ERS could  be  a  long  one,  but  it is  certainly  going
o be  exiting.  The  articles  presented  in  the  issue  of
he Journal  of  Infection  and  Public  Health  reﬂects
n the  signiﬁcant  developments  and  milestones  of
his journey.
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